** Shares of drugmaker TG Therapeutics TGTX.O rise 5.9% to $29.31 premarket
** Co forecasts preliminary Q4 net product revenue of $103.6 mln vs analysts' avg. est. of $97.69 mln - data compiled by LSEG
** Sees full-year 2024 net product revenue of $310 mln, above est. of $304.1 mln
** TGTX expects to end 2024 with cash position of about $310 mln
** Co forecasts 2025 total revenue of about $540 mln vs est. of $549.5 mln
** Up to last close, stock had risen 62.5% in past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。